Loading stock data…
Repligen Corporation (RGEN)
$137.00-10.01 (-6.81%)
After Hours$137.00+0.00 (+0.00%)· Last close Jun 29
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Repligen Corporation in the Healthcare sector is trading at $137.00 with a market capitalization of $6.9B. Wall Street consensus targets $176.11 (19 analysts), implying a +28.5% move over the next 12 months. The stock is currently 22% below its 52-week high of $175.77, remaining 1.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $194.25M↓ | $197.91M↑ | $188.81M↑ | $182.37M↑ | $169.17M |
| Gross Profit | $108.28M↑ | $103.83M↑ | $100.52M↑ | $91.14M↓ | $91.37M |
| Operating Income | $17.29M↑ | $16.35M↑ | $12.68M↑ | $5.96M↓ | $8.55M |
| Net Income | $8.33M↓ | $13.29M↓ | $14.91M↑ | $14.87M↑ | $5.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
133.77
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.44%
Volume
Today's trading volume
1.76M
Recent News
2 High-Flying Stocks on Our Watchlist and 1 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
Repligen Corporation (RGEN) Dropped Following the Earnings Release
Brown Capital Management, an investment management company, released its first quarter 2026 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the first quarter of 2026, the Small Company Fund (Investor shares) fell 19.78%, significantly lagging the Russell 2000 Growth index’s 2.81% decline. Worsened […]
2 Profitable Stocks on Our Watchlist and 1 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools
Osterweis Capital Management, an investment management firm, released its Q1 2026 investor update for its “Osterweis Opportunity Fund”. A copy of the letter can be downloaded here. The fund returned -3.78% in the quarter compared to -2.81% for the Russell 2000 Growth Index. The fund’s long-term returns stay positive, but recent geopolitical shocks and AI […]
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.